Overview:
The management of esophagogastric adenocarcinoma has evolved substantially with the introduction of effective targeted and immunologic therapies. However, these therapies are appropriate mainly for patients with specific biomarkers, necessitating careful coordination among the multidisciplinary team to ensure proper tissue stewardship and testing, which in turn allows for appropriate treatment selection and sequencing, as well as management and mitigation of adverse events.
In this live, virtual webcast, experts in the management of
esophagogastric adenocarcinoma discuss the principles for molecular testing in
these cancers, with a particular focus on identifying HER2-positive disease, as
well as outlining key decision points for treatment. These points will be
discussed in the context of patient case scenarios that highlight challenges in
the management of HER2-positive esophagogastric cancers.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Apply best practices for HER2 biomarker testing in patients with GEA to guide timely, individualized treatment decisions
- Incorporate the latest evidence on HER2-directed therapies into individualized treatment plans for patients with advanced GEA
Target Audience:
This educational program is primarily directed toward
medical oncologists, molecular pathologists, radiologists, gastroenterologists,
advanced practice providers, and nurses who are involved in the management of
patients with advanced or metastatic gastroesophageal adenocarcinomas (GEA).

Yelena Y. Janjigian, MD
Carroll and Milton Petrie Chair
Professor and Chief Attending
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Michal F. Segal, BSN, OCN
Clinical Trials Nurse
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Amitabh Srivastava, MBBS
Memorial Sloan Kettering Cancer Center
New York, NY
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Medical Oncologists (ABIM)

Successful completion of this CME
activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0
MOC points in the American Board of Internal Medicine’s (ABIM).
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the CME
activity provider’s responsibility to submit participant completion information
to ACCME for the purpose of granting ABIM MOC credit.



